ReviewNature reviews. Clinical oncology2012
From drug discovery to biomarker-driven clinical trials in lymphoma.
Review in Nature reviews. Clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Transcriptomics analysis unveils the complex interplay between diabetes and hypertension in regulating renal cell carcinoma pathway followed by pancreatic metastasis.Journal, genetic engineering & biotechnology · 2025Article
- LBD: a manually curated database of experimentally validated lymphoma biomarkers.Database : the journal of biological databases and curation · 2022Article
- Precision Medicine in Lymphoma by Innovative Instrumental Platforms.Frontiers in oncology · 2019Review
- Article
- Clinical applications of genome studies.Hematological oncology · 2017Review
- Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.PloS one · 2016Review
- Precision medicine in diffuse large B-cell lymphoma: hitting the target.Haematologica · 2015Article
- On chip analysis of CNS lymphoma in cerebrospinal fluid.Theranostics · 2015Article
- Precision therapy for lymphoma--current state and future directions.Nature reviews. Clinical oncology · 2014Review
- Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.Annals of hematology · 2014Review
- Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.Scientific reports · 2014Article
- Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Autophagy plays a critical role in ChLym-1-induced cytotoxicity of non-hodgkin's lymphoma cells.PloS one · 2013Article
- Haematological cancer: Hit the lymphoma, JAK.Nature reviews. Clinical oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Over the past three decades, the pathological classification of lymphoma has substantially improved. The early Rappaport classification included a handful of subtypes that did not reflect the cell of origin and, not surprisingly, resulted in diagnostic inaccuracies. The WHO currently classifies lymphoma into 30 major distinctive types. While this classification improved the accuracy and consistency of the histological diagnosis of lymphoma, it had little impact on advancing drug development or improving the cure rate of this disease. One reason for this lack of improvement is that recent developments in cancer genomics show these histopathological subtypes to be heterogeneous. Basing treatment decisions on histopathological subtypes is inefficient as it groups different underlying molecular characteristics into one category. Such a strategy exposes many patients to potentially toxic drugs without providing benefits. The recent approval of two new cancer drugs with companion diagnostics to allow selection and treatment of patients with melanoma and non-small-cell lung cancer has raised hope that a similar approach may also expedite successful drug development in lymphoma. We review the current status of biomarker development in lymphoma, and discuss novel biomarker-directed clinical trial designs for lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.